{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:47:21Z","timestamp":1783792041833,"version":"3.55.0"},"reference-count":163,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/100009770","name":"NUI Galway Hardiman Research Scholarship 2016","doi-asserted-by":"publisher","award":["Postgraduate Scholarship GOIPG\/2017\/1170"],"award-info":[{"award-number":["Postgraduate Scholarship GOIPG\/2017\/1170"]}],"id":[{"id":"10.13039\/100009770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["Postgraduate Scholarship GOIPG\/2018\/38"],"award-info":[{"award-number":["Postgraduate Scholarship GOIPG\/2018\/38"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The development of metallodrugs with potential applications in cancer\ntreatment and diagnosis has been a hot topic since the approval and subsequent marketing of the anticancer\ndrug cisplatin in 1978. Since then, thousands of metal-based derivatives have been reported\nand evaluated for their chemotherapeutic or tumor imaging properties, but only a very limited\nnumber gained clinical status. Nonetheless, research in the field has been increasing exponentially\nover the years, especially in a view to exploiting novel drug designing approaches and strategies\naimed at improving pharmacological outcomes and, at the same time, reducing side-effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This review article reports on the patents filed during the last decade and strictly focusing\non the development of metal-based anticancer and diagnostic agents. The goal is to identify the\nlatest trends and designing strategies in the field, which would represent a valuable starting point to\nresearchers interested in the development of metallodrugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The most relevant patents filed in the 2010-2020 timeframe have been retrieved from\nvarious databases using dedicated search engines (such as SciFinder, Google Patents, PatentPak,\nEspacenet, Global Dossier, PatentScope), sorted by type of metallodrug and screened to include\nthose reporting a substantial amount of biological data.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results :<\/jats:title>\n<jats:p>The majority of patents here reviewed are concerned with metallodrugs (mostly platinum-\nbased) showing interesting pharmacological properties but no specific tumor-targeting features.\nNonetheless, some promising trends in the development of novel drug delivery strategies\nand\/or metallodrugs with potential applications in targeted chemotherapy are envisaged.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In this review, the latest trends in the development of metallodrugs from recent patents\nare summarized and critically discussed. Such trends would be of interest not only to the scientific\ncommunity but also to lay audiences aiming to broaden their knowledge of the field and industrial\nstakeholders potentially interested in the exploitation and commercialization of this class\nof pharmaceuticals.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892816666210907101146","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T04:55:59Z","timestamp":1631076959000},"page":"42-54","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Metallodrugs as Anticancer Chemotherapeutics and Diagnostic Agents: A\nCritical Patent Review (2010-2020)"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-8364","authenticated-orcid":true,"given":"Luca","family":"Ronconi","sequence":"first","affiliation":[{"name":"School of Chemistry, College of Science and Engineering, National University of Ireland Galway, University Road,\nGalway H91, TK33, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-5629","authenticated-orcid":true,"given":"Eirini","family":"Fotopoulou","sequence":"additional","affiliation":[{"name":"School of Chemistry, College of Science and Engineering, National University of Ireland Galway, University Road,\nGalway H91, TK33, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-3975","authenticated-orcid":true,"given":"Ioannis","family":"Titilas","sequence":"additional","affiliation":[{"name":"School of Chemistry, College of Science and Engineering, National University of Ireland Galway, University Road,\nGalway H91, TK33, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s40140-018-0294-1","volume":"8","author":"McCormick P.J.","year":"2018","unstructured":"McCormick P.J.; Cancer tsunami: Emerging trends, economic burden, and perioperative implications. Curr Anesthesiol Rep 2018,8(4),348-354","journal-title":"Curr Anesthesiol Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"Miller K.D.","year":"2019","unstructured":"Miller K.D.; Nogueira L.; Mariotto A.B.; Rowland J.H.; Yabroff K.R.; Alfano C.M.; Jemal A.; Kramer J.L.; Siegel R.L.; Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019,69(5),363-385","journal-title":"CA Cancer J Clin"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/156802612799078964","volume":"12","author":"Komeda S.","year":"2012","unstructured":"Komeda S.; Casini A.; Next-generation anticancer metallodrugs. Curr Top Med Chem 2012,12(3),219-235","journal-title":"Curr Top Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"Ghosh S.","year":"2019","unstructured":"Ghosh S.; Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019,88,102925","journal-title":"Bioorg Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.13005\/bpj\/1608","volume":"12","author":"Aldossary S.A.","year":"2019","unstructured":"Aldossary S.A.; Review on pharmacology of Cisplatin: Clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J 2019,12(1),7-15","journal-title":"Biomed Pharmacol J"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0898-8838(08)60271-8","volume":"49","author":"Guo Z.","year":"1999","unstructured":"Guo Z.; Sadler P.J.; Medicinal inorganic chemistry. Adv Inorg Chem 1999,49,183-306","journal-title":"Adv Inorg Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"Kelland L.","year":"2007","unstructured":"Kelland L.; The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007,7(8),573-584","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"Johnstone T.C.","year":"2016","unstructured":"Johnstone T.C.; Suntharalingam K.; Lippard S.J.; The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 2016,116(5),3436-3486","journal-title":"Chem Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4155\/fmc-2017-0317","volume":"10","author":"Hanif M.","year":"2018","unstructured":"Hanif M.; Hartinger C.G.; Anticancer metallodrugs: Where is the next cisplatin? Future Med Chem 2018,10(6),615-617","journal-title":"Future Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cbpa.2019.11.001","volume":"56","author":"Murray B.S.","year":"2020","unstructured":"Murray B.S.; Dyson P.J.; Recent progress in the development of organometallics for the treatment of cancer. Curr Opin Chem Biol 2020,56,28-34","journal-title":"Curr Opin Chem Biol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/inorganics7070088","volume":"7","author":"Contel M.","year":"2019","unstructured":"Contel M.; Unconventional anticancer metallodrugs and strategies to improve their pharmacological profile. Inorganics (Basel) 2019,7(7),88","journal-title":"Inorganics (Basel)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1039\/c0dt00292e","volume":"39","author":"Wheate N.J.","year":"2010","unstructured":"Wheate N.J.; Walker S.; Craig G.E.; Oun R.; The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010,39(35),8113-8127","journal-title":"Dalton Trans"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.1039\/D0SC04082G","volume":"11","author":"Anthony E.J.","year":"2020","unstructured":"Anthony E.J.; Bolitho E.M.; Bridgewater H.E.; Carter O.W.L.; Donnelly J.M.; Imberti C.; Lant E.C.; Lermyte F.; Needham R.J.; Palau M.; Sadler P.J.; Shi H.; Wang F.X.; Zhang W.Y.; Zhang Z.; Metallodrugs are unique: Opportunities and challenges of discovery and development. Chem Sci (Camb) 2020,11(48),12888-12917","journal-title":"Chem Sci (Camb)"},{"key":"ref=15","unstructured":"SciFinder - chemical abstracts service. Available from:  [Last accessed on February 26, 2021]"},{"key":"ref=16","author":"Che C.M.","year":"2014","unstructured":"Che C.M.; Metal complexes of thiourea and derivatives as metal delivering anti-cancer and anti-inflammatory agents. 2014"},{"key":"ref=17","author":"Akerman K.J.","year":"2012","unstructured":"Akerman K.J.; Akerman P.; Munro O.Q.; Gold complexes for use in the treatment of cancer. 2012"},{"key":"ref=18","author":"Mandal S.S.","year":"2012","unstructured":"Mandal S.S.; Ansari K.I.; Grant J.D.; Apoptotic and anti-tumor activities of metallo-salens. 2012"},{"key":"ref=19","author":"Che C.M.","year":"2014","unstructured":"Che C.M.; Sun W.R.; Chow L.; Yan J.; Pharmaceutical composition containing cyclometalated n-heterocyclic carbene complexes for cancer treatment. 2014"},{"key":"ref=20","author":"Che C.M.","year":"2014","unstructured":"Che C.M.; Zou T.; Novel gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection. 2014"},{"key":"ref=21","author":"Szczepaniak S.","year":"2019","unstructured":"Szczepaniak S.; Szczepaniak E.; Szczepaniak R.; Szczepaniak D.; Szczepaniak M.; Water-soluble gold (III) complexes, methods of producing water-soluble gold (III) complexes and their use. 2019"},{"key":"ref=22","author":"Al-Jaroudi S.","year":"2016","unstructured":"Al-Jaroudi S.; Altaf M.; Al-Saadi A.; Isab A.A.; Mixed ligand gold (III) complexes and methods thereof. 2016"},{"key":"ref=23","author":"Munro O.Q.","year":"2016","unstructured":"Munro O.Q.; Akerman K.J.; Akerman P.; Gold complexes for use in the treatment of cancer. 2016"},{"key":"ref=24","author":"Contel M.","year":"2016","unstructured":"Contel M.; Fernandez-Gallardo J.; Elie B.T.; Ramos J.W.; Titanocene-gold derivatives comprising thiolato ligands. 2016"},{"key":"ref=25","author":"Al-Jaroudi S.","year":"2016","unstructured":"Al-Jaroudi S.; Altaf M.; Al-Saadi A.; Isab A.A.; Mixed ligand gold (III) complexes as anti-cancer agents. 2016"},{"key":"ref=26","author":"Al-Jaroudi S.","year":"2017","unstructured":"Al-Jaroudi S.; Altaf M.; Al-Saadi A.; Isab A.A.; Method for treating prostate cancer and\/or gastrointestinal cancer. 2017"},{"key":"ref=27","author":"Al-Jaroudi S.S.","year":"2018","unstructured":"Al-Jaroudi S.S.; Alhoshani A.; Altaf M.; Isab A.A.; Mixed ligand gold (I) complexes as anti-cancer agents. 2018"},{"key":"ref=28","author":"Al-Jaroudi S.S.","year":"2019","unstructured":"Al-Jaroudi S.S.; Alhoshani A.; Altaf M.; Isab A.A.; Cancer cell-containing composition. 2019"},{"key":"ref=29","author":"Al-Jaroudi S.S.","year":"2019","unstructured":"Al-Jaroudi S.S.; Alhoshani A.; Altaf M.; Isab A.A.; Gold complex- containing cancer activity composition. 2019"},{"key":"ref=30","author":"Ishikawa Y.","year":"2019","unstructured":"Ishikawa Y.; Eguchi H.; Metal salen complex compound, local anesthetic, and anti-malignant tumor agent. 2019"},{"key":"ref=31","author":"Ishikawa Y.","year":"2016","unstructured":"Ishikawa Y.; Eguchi H.; Anti-cancer agent and method for killing cancer cells. 2016"},{"key":"ref=32","author":"Nagai M.","year":"2015","unstructured":"Nagai M.; Shen J.; Transition metal complexes of bis[thiohydrazide amide] compounds. 2015"},{"key":"ref=33","author":"Cowan J.A.","year":"2014","unstructured":"Cowan J.A.; Cowan A.S.; Palmer D.T.; Metallodrugs having improved pharmacological properties, and methods of manufacture and use thereof. 2014"},{"key":"ref=34","author":"Marzano C.","year":"2015","unstructured":"Marzano C.; Porchia M.; Tisato F.; Gandin V.; Santini C.; Pellei M.; Lobbia G.G.; Papini G.; [CU(thp)4]n[X]-n compounds for the treatment of a broad range of human solid tumors, including refractory tumors. 2015"},{"key":"ref=35","author":"Jaouen G.","year":"2013","unstructured":"Jaouen G.; Vessieres-Jaouen A.; Plazuk D.; Ferrocene derivatives with anticancer activity. 2013"},{"key":"ref=36","author":"Anselmo Viegas Garcia M.H.","year":"2013","unstructured":"Anselmo Viegas Garcia M.H.; Ferreira Morais T.S.; Antunes Tomaz Diniz A.I.; Marujo Marques F.; Fernandes Mendes F.; Transition metal complexes for pharmaceutical applications. 2013"},{"key":"ref=37","author":"Demirci T.B.","year":"2018","unstructured":"Demirci T.B.; Ulk\u00fcseven B.; Kuruca D.S.; New thiosemicarbazone chelates having anticancer activity. 2018"},{"key":"ref=38","author":"Sheshbaradaran H.","year":"2017","unstructured":"Sheshbaradaran H.; Method to prevent cancer metastasis to bone. 2017"},{"key":"ref=39","author":"Hlavinka M.L.","year":"2016","unstructured":"Hlavinka M.L.; Yang Q.; Murph M.M.; Use of metallocene compounds for cancer treatment. 2016"},{"key":"ref=40","author":"Piccariello T.","year":"2010","unstructured":"Piccariello T.; Metal coordinated compositions. 2010"},{"key":"ref=41","author":"Piccariello T.","year":"2013","unstructured":"Piccariello T.; Metal coordinated compositions. 2013"},{"key":"ref=42","author":"Piccariello T.","year":"2014","unstructured":"Piccariello T.; Price J.D.; Oberlender R.A.; Mulhare M.E.; Spencer M.C.; Palmer S.B.; Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients. 2014"},{"key":"ref=43","author":"Odani A.","year":"2011","unstructured":"Odani A.; Metal complexes and anticancer agents comprising same as active ingredient. 2011"},{"key":"ref=44","author":"I\u00e7sel C.","year":"2017","unstructured":"I\u00e7sel C.; Ulukaya E.; Yilmaz V.T.; Dimas K.; Palladium complex with high anticancer activity. 2017"},{"key":"ref=45","author":"Liu Y.","year":"2014","unstructured":"Liu Y.; Wang Y.; Application of water soluble platinum complex to preparation of tumor prevention and treatment medicines. 2014"},{"key":"ref=46","author":"Liu Y.","year":"2014","unstructured":"Liu Y.; Wang Y.; Application of fluorine-containing water-soluble platinum complex to preparation of tumor prevention and treatment medicines. 2014"},{"key":"ref=47","author":"Braley C.","year":"2011","unstructured":"Braley C.; Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound. 2011"},{"key":"ref=48","author":"Chang Q.","year":"2012","unstructured":"Chang Q.; Hou S.; Li X.; Li Y.; Liu W.; Shen X.; Su J.; Ye Q.; Yu Y.; Platinum(II) anti-cancer compound with selectivity for cancer cells. 2012"},{"key":"ref=49","author":"Bierbach U.","year":"2013","unstructured":"Bierbach U.; Ding S.; Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof. 2013"},{"key":"ref=50","author":"Jiaju S.","year":"2013","unstructured":"Jiaju S.; Yiguan Z.; Dynamic anti-cancer platinum compound with two different ligands at syn-position. 2013"},{"key":"ref=51","author":"Shaohua G.","year":"2013","unstructured":"Shaohua G.; Gang X.; Antitumor platinum(II) complex and use thereof in preparation of antitumor medicine. 2013"},{"key":"ref=52","author":"Cheng Q.","year":"2013","unstructured":"Cheng Q.; Liu Y.; Min Y.; Shi H.; Anti-cancer medicinal aspirin platinum complex and preparation method thereof. 2013"},{"key":"ref=53","author":"Chen X.","year":"2013","unstructured":"Chen X.; Hou S.; Liu W.; Lou L.; Quan H.; Xie C.; Ye Q.; Dichloroacetoxyl-containing platinum(II) anticancer coordination compound. 2013"},{"key":"ref=54","author":"Huang H.","year":"2013","unstructured":"Huang H.; Ji L.; Mao Z.; Tan C.; Zheng X.; Organic hydridized tetra- core platinum complex and preparation method thereof as well as application in antitumor medicament preparation. 2013"},{"key":"ref=55","author":"Yong Hei","year":"2014","unstructured":"Yong Hei; Combination of motesanib, a taxane and a platinum- containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset. 2014"},{"key":"ref=56","author":"Shi S.","year":"2014","unstructured":"Shi S.; Wang X.; Yao T.; Novel latent antitumor drug platinum complex and preparation method thereof. 2014"},{"key":"ref=57","author":"Peng J.","year":"2014","unstructured":"Peng J.; Pu S.; Wang Q.; Novel synthetic method of antitumor drug heptyl platinum. 2014"},{"key":"ref=58","author":"Hoeschele J.D.","year":"2015","unstructured":"Hoeschele J.D.; Margiotta N.; Gandin V.; Petruzzella E.; Marzano C.; Method of treating colorectal cancer. 2015"},{"key":"ref=59","author":"Giacomini K.M.","year":"2015","unstructured":"Giacomini K.M.; More S.; Platinum anticancer agents. 2015"},{"key":"ref=60","author":"Hou S.","year":"2015","unstructured":"Hou S.; Jiang J.; Liu W.; Lou L.; Sun L.; Xie C.; Ye Q.; Platinum(II) antitumor compounds taking 3-oxo-cyclobutane-1,1-dicarboxylate as ligand. 2015"},{"key":"ref=61","author":"Gou S.","year":"2015","unstructured":"Gou S.; Zhao J.; Antitumor platinum(II) complex by taking alkyl carboxylate radical as ligand. 2015"},{"key":"ref=62","author":"Lu L.","year":"2015","unstructured":"Lu L.; Yuan C.; Zhu M.; Binuclear platinum(II) complex as well as preparation method and application thereof. 2015"},{"key":"ref=63","author":"Gou S.","year":"2016","unstructured":"Gou S.; Anti-tumor bivalent platinum complex and preparation method for complex and ligand of complex. 2016"},{"key":"ref=64","author":"Davey C.A.","year":"2016","unstructured":"Davey C.A.; Ang W.H.; Chin C.F.; Platinum complexes as anticancer agents. 2016"},{"key":"ref=65","author":"Yu Y.","year":"2016","unstructured":"Yu Y.; A kind of Pt(IV with mixing axial part) kind anti-cancer drugs thing and preparation method. 2016"},{"key":"ref=66","author":"Miodragovic D.U.","year":"2016","unstructured":"Miodragovic D.U.; O'Halloran T.V.; Arsenoplatin anti-cancer agents. 2016"},{"key":"ref=67","author":"Bierbach U.","year":"2017","unstructured":"Bierbach U.; Ding S.; Cleavable conjugates of functionalized platinum-acridine and platinum-benzacridine agents and methods thereof. 2017"},{"key":"ref=68","author":"Lu L.","year":"2017","unstructured":"Lu L.; Wu Y.; Yuan C.; Zhu M.; A kind of Schiff bases platinum complex and its preparation method and application. 2017"},{"key":"ref=69","author":"Isab A.H.A.K.","year":"2017","unstructured":"Isab A.H.A.K.; Altaf M.; Bis-(triethylphosphine)platinum(II) complexes with thiones as anti-cancer agents. 2017"},{"key":"ref=70","author":"Giacomini K.M.","year":"2017","unstructured":"Giacomini K.M.; More S.; Yee S.W.; Geier E.; Wilson J.; Platinum anticancer agents. 2017"},{"key":"ref=71","author":"Chen X.","year":"2017","unstructured":"Chen X.; Yan Y.; Meng X.; Zhao F.; Gao Z.; Wen S.; Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino. 2017"},{"key":"ref=72","author":"Zhu G.","year":"2017","unstructured":"Zhu G.; Ma L.; Heterodinuclear platinum-ruthenium complexes, preparation thereof and therapeutic use thereof. 2017"},{"key":"ref=73","author":"Che C.M.","year":"2018","unstructured":"Che C.M.; Hu D.; Chan L.F.; Platinum complexes and methods of use thereof. 2018"},{"key":"ref=74","author":"Gamble A.J.","year":"2013","unstructured":"Gamble A.J.; Lynam J.M.; Walton P.H.; Synthesis and anticancer activity of ruthenium (11) cis-cis-1,3,5- triaminocyclohexane complexes. 2013"},{"key":"ref=75","author":"Reddy V.D.","year":"2014","unstructured":"Reddy V.D.; Organometallic anti-cancer complexes. 2014"},{"key":"ref=76","author":"Garnett M.","year":"2017","unstructured":"Garnett M.; Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors. 2017"},{"key":"ref=77","author":"Gao L.","year":"2015","unstructured":"Gao L.; Jiang J.; Li L.; Li Y.; Liu W.; Shen X.; Zhang J.; Zhou H.; Two (\u03b1-furnancarboxylic acid) vanadyl is as the novelty teabag of cancer therapy drug. 2015"},{"key":"ref=78","author":"Meijboom R.","year":"2017","unstructured":"Meijboom R.; Cronje M.J.; Use of silver(I) complexes as anticancer agents. 2017"},{"key":"ref=79","author":"Yen M.A.","year":"2018","unstructured":"Yen M.A.; Gray H.B.; Grubbs R.H.; Palmer J.; Derivatized corroles and metallocorroles and their use as imaging and therapeutic agents. 2018"},{"key":"ref=80","author":"Lascola C.D.","year":"2017","unstructured":"Lascola C.D.; Manganese complexes with substituted bisphosphonates useful as imaging and therapeutic agents. 2017"},{"key":"ref=81","author":"Du Preez J.G.H.","year":"2013","unstructured":"Du Preez J.G.H.; Wentzel M.; Knoetze D.; Aromatic compounds and metal complexes thereof. 2013"},{"key":"ref=82","author":"Biswas G.","year":"2017","unstructured":"Biswas G.; Dutta P.; Mandal S.K.; Modi S.; Raj J.P.; Sarkar A.; Sengupta A.; Sharma R.; Suryavanshi H.; Fluorescent anticancer platinum drugs. 2017"},{"key":"ref=83","author":"Frank S.J.","year":"2017","unstructured":"Frank S.J.; Martirosyan K.; Cobalt-based MRI contrast agent and imaging system. 2017"},{"key":"ref=84","author":"Yang J.J.","year":"2018","unstructured":"Yang J.J.; Liu Z.; Li S.; Zhou Y.; Jiang J.; Xue S.; Qiao J.; Wei L.; Contrast agents, methods for preparing contrast agents, and methods of imaging. 2018"},{"key":"ref=85","author":"Kundra V.","year":"2015","unstructured":"Kundra V.; Bankson J.A.; Annapragada A.; Ghaghada K.B.; Ravoori M.K.; Dual mode gadolinium nanoparticle contrast agents. 2015"},{"key":"ref=86","author":"Gibson D.","year":"2017","unstructured":"Gibson D.; Pt(IV) prodrugs. 2017"},{"key":"ref=87","author":"Nakamura M.","year":"2020","unstructured":"Nakamura M.; Fukuda T.; Yamakawa K.; Novel platinum (IV) complex. 2020"},{"key":"ref=88","author":"Dhar S.","year":"2015","unstructured":"Dhar S.; Pathak R.; Marrache S.; Mitochondria-targeting platinum(IV) prodrug. 2015"},{"key":"ref=89","author":"Lippard S.J.","year":"2015","unstructured":"Lippard S.J.; Song Y.; Suntharalingam K.; Dual targeting anticancer agents. 2015"},{"key":"ref=90","author":"McFarland S.A.","year":"2020","unstructured":"McFarland S.A.; Metal-based coordination complexes as photodynamic compounds and their use. 2020"},{"key":"ref=91","author":"Mandel A.","year":"2017","unstructured":"Mandel A.; Metal-glycoprotein complexes and their use as chemotherapeutic compounds.. 2017"},{"key":"ref=92","author":"Cai Z.","year":"2015","unstructured":"Cai Z.; Cang H.; Sun B.; Sun Y.; Zhang H.; Chitosan-platinum(IV) prodrug conjugate and preparation method thereof. 2015"},{"key":"ref=93","author":"Wong K.L.","year":"2017","unstructured":"Wong K.L.; Wong W.K.; Multi-modal bioprobe for bladder cancer imaging and photodynamic therapy. 2017"},{"key":"ref=94","author":"Lin W.","year":"2017","unstructured":"Lin W.; Liu D.; Della Rocca J.; Kramer S.A.; Poon C.Y.; Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders. 2017"},{"key":"ref=95","author":"Messersmith P.B.","year":"2014","unstructured":"Messersmith P.B.; Black K.C.L.; Yi J.; Rivera J.G.; Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same. 2014"},{"key":"ref=96","author":"Koob T.J.","year":"2015","unstructured":"Koob T.J.; Cross-linked collagen comprising metallic anticancer agents. 2015"},{"key":"ref=97","author":"Jun Y.J.","year":"2011","unstructured":"Jun Y.J.; Sohn Y.S.; Tumor cell-selective and long-circulating micellar platinum anticancer agent and preparation method thereof. 2011"},{"key":"ref=98","author":"Hu X.","year":"2013","unstructured":"Hu X.; Huang Y.; Jing X.; Liu S.; Qi R.; Xiao H.; Zheng Y.; Zhou D.; Biodegradable high-polymer bonded photoactive Pt(IV) anticancer medicament micelle and preparation method thereof. 2013"},{"key":"ref=99","author":"Lin I.J.B.","year":"2018","unstructured":"Lin I.J.B.; Hsu T.H.T.; Chou S.-H.; Nanoparticles containing azolium and N-heterocyclic carbene compounds and use thereof. 2018"},{"key":"ref=100","author":"Farokhzad O.C.","year":"2014","unstructured":"Farokhzad O.C.; Gadde SS.; Karnik R.; Langer R.S.; Lippard S.J.; Pridgen E.M.; Valencia P.M.; Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use. 2014"},{"key":"ref=101","author":"Abidi W.","year":"2017","unstructured":"Abidi W.; Cao P.; Berlin J.; Aboody K.; Mooney R.; Silica nanoparticle with platinum anti-cancer agent. 2017"},{"key":"ref=102","author":"Lin W.","year":"2020","unstructured":"Lin W.; He C.; Lu K.; Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof. 2020"},{"key":"ref=103","author":"Che C.M.","year":"2017","unstructured":"Che C.M.; Chung Y.S.C.; Gold porphyrin-PEG conjugates and methods of use. 2017"},{"key":"ref=104","author":"Lin S.-Y.","year":"2015","unstructured":"Lin S.-Y.; Caged platinum nanoclusters for anticancer chemotherapeutics. 2015"},{"key":"ref=105","author":"Fukunaga H.","year":"2017","unstructured":"Fukunaga H.; Dozono H.; Hino A.; Oshikiri S.; Nagano A.; Novel nitrogen-containing compound or salt thereof, or metal complex thereof. 2017"},{"key":"ref=106","author":"Alberto R.","year":"2010","unstructured":"Alberto R.; Kunze S.B.; Castro H.K.; Mundwiler S.; Metal complexes having vitamin B12 as a ligand. 2010"},{"key":"ref=107","author":"Contel M.","year":"2020","unstructured":"Contel M.; Curado N.; Lewis J.; Poty S.; Antibody-drug conjugates based on gold compounds. 2020"},{"key":"ref=108","author":"Yano S.","year":"2017","unstructured":"Yano S.; Shibahara T.; Ogura S.; Amino sugar-linked anticancer noble metal complex. 2017"},{"key":"ref=109","author":"Chen H.","year":"2011","unstructured":"Chen H.; Liu P.; Gao Q.; Lu Y.; Glucose-containing platinum complex for treating tumors and preparation method thereof. 2011"},{"key":"ref=110","author":"Chen H.","year":"2011","unstructured":"Chen H.; Gao Q.; Liu P.; Lu Y.; Galactose-containing platinum complex for tumour targeted therapy and preparation method thereof. 2011"},{"key":"ref=111","author":"Liu Y.","year":"2012","unstructured":"Liu Y.; Wang Y.; Application of sugar-containing platinum complex in preparation of medicines for preventing and treating tumor. 2012"},{"key":"ref=112","author":"Wang P.","year":"2018","unstructured":"Wang P.; Wang Q.; Wang X.; Glycosylation tetravalence platinum- like compounds with active anticancer, preparation method and application. 2018"},{"key":"ref=113","author":"Chang Q.","year":"2016","unstructured":"Chang Q.; Hou S.; Jiang J.; Liu W.; Lou L.; Ye Q.; Liver target platinum-containing anticancer drug and synthetic method thereof. 2016"},{"key":"ref=114","author":"Krause M.E.","year":"2015","unstructured":"Krause M.E.; Laurence G.; Mu Q.X.; Stowell L.J.A.; Therapeutic metal complexes. 2015"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3892\/ijmm.2016.2744","volume":"38","author":"Xiao Y.D.","year":"2016","unstructured":"Xiao Y.D.; Paudel R.; Liu J.; Ma C.; Zhang Z.S.; Zhou S.K.; MRI contrast agents: Classification and application (Review). Int J Mol Med 2016,38(5),1319-1326","journal-title":"Int J Mol Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1021\/acs.bioconjchem.9b00499","volume":"30","author":"Akakuru O.U.","year":"2019","unstructured":"Akakuru O.U.; Iqbal M.Z.; Saeed M.; Liu C.; Paunesku T.; Woloschak G.; Hosmane N.S.; Wu A.; The transition from metal-based to metal-free contrast agents for T magnetic resonance imaging enhancement. Bioconjug Chem 2019,30(9),2264-2286","journal-title":"Bioconjug Chem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ejic.201601278","volume":"12","author":"Kenny R.G.","year":"2017","unstructured":"Kenny R.G.; Chuah S.W.; Crawford A.; Marmion C.J.; Platinum(IV) prodrugs - a step closer to Ehrlich\u2019s vision? Eur J Inorg Chem 2017,12,1596-1612","journal-title":"Eur J Inorg Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1039\/C8DT03923B","volume":"48","author":"Wang Z.","year":"2019","unstructured":"Wang Z.; Deng Z.; Zhu G.; Emerging platinum(iv) prodrugs to combat cisplatin resistance: From isolated cancer cells to tumor microenvironment. Dalton Trans 2019,48(8),2536-2544","journal-title":"Dalton Trans"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"12992","DOI":"10.1039\/C6DT01738J","volume":"45","author":"Basu U.","year":"2016","unstructured":"Basu U.; Banik B.; Wen R.; Pathak R.K.; Dhar S.; The platin-X series: Activation, targeting, and delivery. Dalton Trans 2016,45(33),12992-13004","journal-title":"Dalton Trans"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"Eckschlager T.","year":"2017","unstructured":"Eckschlager T.; Plch J.; Stiborova M.; Hrabeta J.; Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 2017,18(7),1414","journal-title":"Int J Mol Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"Weinberg S.E.","year":"2015","unstructured":"Weinberg S.E.; Chandel N.S.; Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 2015,11(1),9-15","journal-title":"Nat Chem Biol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbt.21833","volume":"31","author":"Darwish M.A.","year":"2017","unstructured":"Darwish M.A.; Abo-Youssef A.M.; Khalaf M.M.; Abo-Saif A.A.; Saleh I.G.; Abdelghany T.M.; Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative\/nitrosative stress, suppression of inflammation and reduction of total renal platinum accumulation. J Biochem Mol Toxicol 2017,31(1),1-9","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=123","first-page":"25","volume":"5","author":"Ferreira dos Santos A.","year":"2019","unstructured":"Ferreira dos Santos A.; Queiroz de Almeida D.R.; Ferreira Terra L.; Baptista M.S.; Labriola L.; Photodynamic therapy in cancer treatment - an update review. J Cancer Metastasis Treat 2019,5,25","journal-title":"J Cancer Metastasis Treat"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1039\/D0CS00173B","volume":"50","author":"Zhao X.","year":"2021","unstructured":"Zhao X.; Liu J.; Fan J.; Chao H.; Peng X.; Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: From molecular design to application. Chem Soc Rev 2021,50(6),4185-4219","journal-title":"Chem Soc Rev"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"10330","DOI":"10.1039\/C8DT01585F","volume":"47","author":"Bonnet S.","year":"2018","unstructured":"Bonnet S.; Why develop photoactivated chemotherapy? Dalton Trans 2018,47(31),10330-10343","journal-title":"Dalton Trans"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/anie.201905171","volume":"59","author":"Imberti C.","year":"2020","unstructured":"Imberti C.; Zhang P.; Huang H.; Sadler P.J.; New designs for phototherapeutic transition metal complexes. Angew Chem Int Ed Engl 2020,59(1),61-73","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/2230-973X.96920","volume":"2","author":"Tiwari G.","year":"2012","unstructured":"Tiwari G.; Tiwari R.; Sriwastawa B.; Bhati L.; Pandey S.; Pandey P.; Bannerjee S.K.; Drug delivery systems: An updated review. Int J Pharm Investig 2012,2(1),2-11","journal-title":"Int J Pharm Investig"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.drudis.2021.01.030","volume":"26","author":"Liu X.Y.","year":"2021","unstructured":"Liu X.Y.; Wang J.Q.; Ashby C.R.; Zeng L.; Fan Y.F.; Chen Z.S.; Gold nanoparticles: Synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today 2021,26(5),1284-1292","journal-title":"Drug Discov Today"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425240903579971","volume":"7","author":"Caldorera-Moore M.","year":"2010","unstructured":"Caldorera-Moore M.; Guimard N.; Shi L.; Roy K.; Designer nanoparticles: Incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010,7(4),479-495","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.2147\/IJN.S165210","volume":"13","author":"Muhamad N.","year":"2018","unstructured":"Muhamad N.; Plengsuriyakarn T.; Na-Bangchang K.; Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional\/herbal medicines in cancer therapy: A systematic review. Int J Nanomedicine 2018,13,3921-3935","journal-title":"Int J Nanomedicine"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/nano10040656","volume":"10","author":"Su S.","year":"2020","unstructured":"Su S.; Kang P.M.; Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials (Basel) 2020,10(4),656","journal-title":"Nanomaterials (Basel)"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1208\/s12249-014-0113-z","volume":"15","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Huang Y.; Li S.; Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 2014,15(4),862-871","journal-title":"AAPS PharmSciTech"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-60761-609-2_3","volume":"624","author":"Greish K.","year":"2010","unstructured":"Greish K.; Enhanced Permeability and Retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010,624,25-37","journal-title":"Methods Mol Biol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","volume":"11","author":"Lu Y.","year":"2018","unstructured":"Lu Y.; Zhang E.; Yang J.; Cao Z.; Strategies to improve micelle stability for drug delivery. Nano Res 2018,11(10),4985-4998","journal-title":"Nano Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.apsb.2017.11.005","volume":"8","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Sun T.; Jiang C.; Biomacromolecules as carriers in drug delivery and tissue engineering. Acta Pharm Sin B 2018,8(1),34-50","journal-title":"Acta Pharm Sin B"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1021\/acs.langmuir.6b01162","volume":"32","author":"Zhao Y.","year":"2016","unstructured":"Zhao Y.; Surface-cross-linked micelles as multifunctionalized organic nanoparticles for controlled release, light harvesting, and catalysis. Langmuir 2016,32(23),5703-5713","journal-title":"Langmuir"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.msec.2017.10.004","volume":"83","author":"Yi Y.","year":"2018","unstructured":"Yi Y.; Lin G.; Chen S.; Liu J.; Zhang H.; Mi P.; Polyester micelles for drug delivery and cancer theranostics: Current achievements, progresses and future perspectives. Mater Sci Eng C 2018,83,218-232","journal-title":"Mater Sci Eng C"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4155\/tde-2020-0008","volume":"11","author":"Majumder N.","year":"2020","unstructured":"Majumder N.; G Das N.; Das S.K.; Polymeric micelles for anticancer drug delivery. Ther Deliv 2020,11(10),613-635","journal-title":"Ther Deliv"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2174\/0929867324666171116125908","volume":"26","author":"Petanidis S.","year":"2019","unstructured":"Petanidis S.; Kioseoglou E.; Salifoglou A.; Metallodrugs in targeted cancer therapeutics: Aiming at chemoresistance- related patterns and immunosuppressive tumor networks. Curr Med Chem 2019,26(4),607-623","journal-title":"Curr Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1021\/ar700093f","volume":"41","author":"Ojima I.","year":"2008","unstructured":"Ojima I.; Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads. Acc Chem Res 2008,41(1),108-119","journal-title":"Acc Chem Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570163812666150602144310","volume":"12","author":"Baudino T.A.","year":"2015","unstructured":"Baudino T.A.; Targeted cancer therapy: The next generation of cancer treatment. Curr Drug Discov Technol 2015,12(1),3-20","journal-title":"Curr Drug Discov Technol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: The next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/cancers11070978","volume":"11","author":"Alday-Parejo B.","year":"2019","unstructured":"Alday-Parejo B.; Stupp R.; R\u00fcegg C.; Are integrins still practicable targets for anti-cancer therapy? Cancers (Basel) 2019,11(7),978","journal-title":"Cancers (Basel)"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1021\/mp3002733","volume":"9","author":"Danhier F.","year":"2012","unstructured":"Danhier F.; Le Breton A.; Pr\u00e9at V.; RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012,9(11),2961-2973","journal-title":"Mol Pharm"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrgastro.2012.76","volume":"9","author":"Nielsen M.J.","year":"2012","unstructured":"Nielsen M.J.; Rasmussen M.R.; Andersen C.B.; Nex\u00f8 E.; Moestrup S.K.; Vitamin B transport from food to the body\u2019s cells-a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol 2012,9(6),345-354","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-07-6771","volume":"68","author":"Waibel R.","year":"2008","unstructured":"Waibel R.; Treichler H.; Schaefer N.G.; van Staveren D.R.; Mundwiler S.; Kunze S.; K\u00fcenzi M.; Alberto R.; N\u00fcesch J.; Knuth A.; Moch H.; Schibli R.; Schubiger P.A.; New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Res 2008,68(8),2904-2911","journal-title":"Cancer Res"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ejic.201601217","volume":"12","author":"Pettenuzzo A.","year":"2017","unstructured":"Pettenuzzo A.; Pigot R.; Ronconi L.; Vitamin B12-metal conjugates for targeted chemotherapy and diagnosis: Current status and future prospects. Eur J Inorg Chem 2017,12,1625-1638","journal-title":"Eur J Inorg Chem"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","volume":"13","author":"Singh S.","year":"2018","unstructured":"Singh S.; Kumar N.K.; Dwiwedi P.; Charan J.; Kaur R.; Sidhu P.; Chugh V.K.; Monoclonal antibodies: A review. Curr Clin Pharmacol 2018,13(2),85-99","journal-title":"Curr Clin Pharmacol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"Zahavi D.","year":"2020","unstructured":"Zahavi D.; Weiner L.; Monoclonal antibodies in cancer therapy. Antibodies (Basel) 2020,9(3),34","journal-title":"Antibodies (Basel)"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"110780","DOI":"10.1016\/j.jinorgbio.2019.110780","volume":"199","author":"Del Solar V.","year":"2019","unstructured":"Del Solar V.; Contel M.; Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. J Inorg Biochem 2019,199,110780","journal-title":"J Inorg Biochem"},{"key":"ref=151","doi-asserted-by":"publisher","DOI":"10.1002\/9780470015902.a0000619.pub3","author":"Harris R.A.","year":"2015","unstructured":"Harris R.A.; Glycolytic pathway. Encyclopedia of life sciences 2015","journal-title":"Encyclopedia of life sciences"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"Vander Heiden M.G.","year":"2009","unstructured":"Vander Heiden M.G.; Cantley L.C.; Thompson C.B.; Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009,324(5930),1029-1033","journal-title":"Science"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/jcp.20166","volume":"202","author":"Macheda M.L.","year":"2005","unstructured":"Macheda M.L.; Rogers S.; Best J.D.; Molecular and cellular regulation of Glucose Transporter (GLUT) proteins in cancer. J Cell Physiol 2005,202(3),654-662","journal-title":"J Cell Physiol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12253-012-9500-5","volume":"18","author":"Krzeslak A.","year":"2012","unstructured":"Krzeslak A.; Wojcik-Krowiranda K.; Forma E.; Jozwiak P.; Romanowicz H.; Bienkiewicz A.; Brys M.; Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012,18(3),721-728","journal-title":"Pathol Oncol Res"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1038\/emm.2013.85","volume":"45","author":"Jang M.","year":"2013","unstructured":"Jang M.; Kim S.S.; Lee J.; Cancer cell metabolism: Implications for therapeutic targets. Exp Mol Med 2013,45(10),e45","journal-title":"Exp Mol Med"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Zhao Y.","year":"2013","unstructured":"Zhao Y.; Butler E.B.; Tan M.; Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013,4(3),e532","journal-title":"Cell Death Dis"},{"key":"ref=157","first-page":"36","volume":"1","author":"Pettenuzzo A.","year":"2015","unstructured":"Pettenuzzo A.; Pigot R.; Ronconi L.; Metal-based glycoconjugates and their potential in targeted anticancer chemotherapy. Metallodrugs 2015,1(1),36-61","journal-title":"Metallodrugs"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/00498250701875254","volume":"38","author":"Rubio-Aliaga I.","year":"2008","unstructured":"Rubio-Aliaga I.; Daniel H.; Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 2008,38(7-8),1022-1042","journal-title":"Xenobiotica"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1021\/mp300364k","volume":"10","author":"Tai W.","year":"2013","unstructured":"Tai W.; Chen Z.; Cheng K.; Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharm 2013,10(2),477-487","journal-title":"Mol Pharm"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1211\/jpp.60.5.0002","volume":"60","author":"Brandsch M.","year":"2008","unstructured":"Brandsch M.; Kn\u00fctter I.; Bosse-Doenecke E.; Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 2008,60(5),543-585","journal-title":"J Pharm Pharmacol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1517\/17425250903042292","volume":"5","author":"Brandsch M.","year":"2009","unstructured":"Brandsch M.; Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin Drug Metab Toxicol 2009,5(8),887-905","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4155\/fmc.14.81","volume":"6","author":"Celegato M.","year":"2014","unstructured":"Celegato M.; Fregona D.; Mongiat M.; Ronconi L.; Borghese C.; Canzonieri V.; Casagrande N.; Nardon C.; Colombatti A.; Aldinucci D.; Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts. Future Med Chem 2014,6(11),1249-1263","journal-title":"Future Med Chem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"Wouters O.J.","year":"2020","unstructured":"Wouters O.J.; McKee M.; Luyten J.; Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 2020,323(9),844-853","journal-title":"JAMA"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892816666210907101146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/196207\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892816666210907101146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T16:58:30Z","timestamp":1665593910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/196207\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":163,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892816666210907101146","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}